Sympathomimetic Imidazolines
Sympathomimetic Imidazolines - Related Videos
01:37
Hypothalamic-Pituitary Axis
0 Views •
2019
The response to stress—be it physical or psychological, acute or chronic—involves activation of the Hypothalamic-Pituitary-Adrenal (HPA) axis. The HPA axis is part of the neuroendocrine system because it involves both neuronal and hormonal communication. Its function is to regulate homeostatic systems—metabolic, cardiovascular, and immune—providing the necessary means to respond to a stressor. What Happens During Stress In response to stress, the neurons in the hypothalamus release...
09:02
Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
0 Views •
Cited by 12 •
2016
In this manuscript, we describe percutaneous isolated hepatic perfusion with simultaneous chemofiltration as treatment for unresectable liver metastases. This procedure is performed under general anaesthesia in the angiosuite by an experienced team, consisting of an interventional radiologist, a clinical perfusionist and anaesthesiologist.
FAQs
Receptor selectivity helps determine whether an agent mainly constricts peripheral vessels or also suppresses sympathetic outflow from the central nervous system. Stimulation of peripheral α-adrenergic receptors supports local vasoconstriction, whereas activation of central α2-adrenergic or imidazoline receptors contributes to autonomic effects. These distinctions help explain why related compounds can serve different therapeutic roles.
Route and duration influence where receptor stimulation occurs, how long effects persist, and the likelihood of systemic adverse reactions. Topical administration can produce localized vascular effects in nasal tissues, while compounds with central activity may affect autonomic function more broadly. Consequently, pharmacological outcomes cannot be interpreted without considering both exposure route and time course.
Rebound congestion is associated with prolonged use of topical agents such as oxymetazoline and xylometazoline. Although these drugs initially constrict vessels in nasal tissues, extended topical administration can be followed by renewed or worsening congestion when the effect is no longer maintained. This outcome makes duration of use an important consideration in pharmacological evaluation.
Oxymetazoline and xylometazoline are used as topical nasal decongestants because their peripheral α-adrenergic effects constrict blood vessels in nasal tissues. Their application illustrates how a sympathomimetic imidazoline can produce a localized therapeutic effect through the administration route. The same example also highlights why prolonged topical use is relevant to rebound congestion.
Clonidine-related compounds are relevant when reducing sympathetic nervous system activity is therapeutically useful in blood pressure management. Their activity at central α2-adrenergic or imidazoline receptors can reduce sympathetic outflow, providing a mechanism distinct from the primarily local vasoconstriction sought with nasal decongestants. Pharmacology therefore uses receptor location and effect to distinguish these applications.
Assessment should include receptor selectivity, administration route, and duration of action. These factors help predict whether a compound will produce mainly local vasoconstriction, central reduction of sympathetic outflow, or broader systemic effects. Comparing the intended therapeutic response with possible systemic adverse reactions also clarifies why closely related imidazoline drugs may require different clinical considerations.